Trial Profile

Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Granulocyte macrophage colony stimulating factor; Imiquimod
Indications Advanced breast cancer; Skin cancer
Focus Adverse reactions

Most Recent Events

15 Jun 2021 Status changed from recruiting to discontinued.
15 Mar 2021 Planned End Date changed from 30 Sep 2024 to 31 Mar 2025.
15 Mar 2021 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com